Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Report

Global and Region Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 31, 2022
  • PAGES：173
  • REPORT CODE：GMM941718
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Non-alcoholic Fatty Liver Disease (NAFLD) Drug market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Non-alcoholic Fatty Liver Disease (NAFLD) Drugmarket, defines the market attractiveness level of Non-alcoholic Fatty Liver Disease (NAFLD) Drug market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Non-alcoholic Fatty Liver Disease (NAFLD) Drug industry, describes the types of Non-alcoholic Fatty Liver Disease (NAFLD) Drug market, the applications of major players and the market size, and deeply analyzes the current situation of the global Non-alcoholic Fatty Liver Disease (NAFLD) Drug market and the development prospects and opportunities of Non-alcoholic Fatty Liver Disease (NAFLD) Drug industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Non-alcoholic Fatty Liver Disease (NAFLD) Drug market in Chapter 13.

    By Player:

    • Metabolic Solutions Development

    • Galmed International

    • Kyorin Pharmaceutical

    • Raptor Pharmaceuticals

    • TCM Biotech International

    • Daewoong Pharmaceutical

    • Phenex Pharmaceuticals

    • Novartis AG

    • Zafgen

    • Verva Pharmaceuticals

    • Tobira Therapeutics

    • Conatus Pharmaceuticals

    By Type:

    • Type 1

    • Type 2

    • Type 3

    By End-User:

    • Application 1

    • Application 2

    • Application 3

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Analysis and Outlook to 2022

    • 7.1 Global Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption (2017-2022)

    • 7.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption (2017-2022)

    • 7.3 Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption (2017-2022)

    • 7.4 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption (2017-2022)

    • 7.5 Japan Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption (2017-2022)

    • 7.6 India Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption (2017-2022)

    • 7.7 South Korea Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption (2017-2022)

    8 Region and Country-wise Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Analysis and Outlook to 2028

    • 8.1 Global Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast (2022-2028)

    • 8.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast (2022-2028)

    • 8.3 Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast (2022-2028)

    • 8.4 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast (2022-2028)

    • 8.5 Japan Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast (2022-2028)

    • 8.6 India Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast (2022-2028)

    • 8.7 South Korea Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast (2022-2028)

    9 Global Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Outlook by Types and Applications to 2022

    • 9.1 Global Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Type 1 Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Type 2 Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Type 3 Consumption and Growth Rate (2017-2022)

    • 9.2 Global Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Application 1 Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Application 2 Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Application 3 Consumption and Growth Rate (2017-2022)

    10 Global Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Outlook by Types and Applications to 2028

    • 10.1 Global Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Type 1 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Type 2 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Type 3 Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Application 1 Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Application 2 Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Application 3 Consumption Forecast and Growth Rate (2022-2028)

    11 Global Non-alcoholic Fatty Liver Disease (NAFLD) Drug Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Non-alcoholic Fatty Liver Disease (NAFLD) Drug Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Non-alcoholic Fatty Liver Disease (NAFLD) Drug Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Competitive Analysis

    • 14.1 Metabolic Solutions Development

      • 14.1.1 Metabolic Solutions Development Company Details

      • 14.1.2 Metabolic Solutions Development Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Metabolic Solutions Development Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • 14.2 Galmed International

      • 14.2.1 Galmed International Company Details

      • 14.2.2 Galmed International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Galmed International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • 14.3 Kyorin Pharmaceutical

      • 14.3.1 Kyorin Pharmaceutical Company Details

      • 14.3.2 Kyorin Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Kyorin Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • 14.4 Raptor Pharmaceuticals

      • 14.4.1 Raptor Pharmaceuticals Company Details

      • 14.4.2 Raptor Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Raptor Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • 14.5 TCM Biotech International

      • 14.5.1 TCM Biotech International Company Details

      • 14.5.2 TCM Biotech International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 TCM Biotech International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • 14.6 Daewoong Pharmaceutical

      • 14.6.1 Daewoong Pharmaceutical Company Details

      • 14.6.2 Daewoong Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Daewoong Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • 14.7 Phenex Pharmaceuticals

      • 14.7.1 Phenex Pharmaceuticals Company Details

      • 14.7.2 Phenex Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Phenex Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • 14.8 Novartis AG

      • 14.8.1 Novartis AG Company Details

      • 14.8.2 Novartis AG Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Novartis AG Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • 14.9 Zafgen

      • 14.9.1 Zafgen Company Details

      • 14.9.2 Zafgen Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Zafgen Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • 14.10 Verva Pharmaceuticals

      • 14.10.1 Verva Pharmaceuticals Company Details

      • 14.10.2 Verva Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Verva Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • 14.11 Tobira Therapeutics

      • 14.11.1 Tobira Therapeutics Company Details

      • 14.11.2 Tobira Therapeutics Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Tobira Therapeutics Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • 14.12 Conatus Pharmaceuticals

      • 14.12.1 Conatus Pharmaceuticals Company Details

      • 14.12.2 Conatus Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Conatus Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Non-alcoholic Fatty Liver Disease (NAFLD) Drug

    • Figure Non-alcoholic Fatty Liver Disease (NAFLD) Drug Picture

    • Table Global Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption by Country (2017-2022)

    • Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption and Growth Rate (2017-2022)

    • Table Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption and Growth Rate (2017-2022)

    • Figure China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption and Growth Rate (2017-2022)

    • Figure Japan Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption and Growth Rate (2017-2022)

    • Figure India Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption and Growth Rate (2017-2022)

    • Figure South Korea Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption and Growth Rate (2017-2022)

    • Figure Global Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast by Country (2022-2028)

    • Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Type 1 Consumption and Growth Rate (2017-2022)

    • Figure Global Type 2 Consumption and Growth Rate (2017-2022)

    • Figure Global Type 3 Consumption and Growth Rate (2017-2022)

    • Figure Global Application 1 Consumption and Growth Rate (2017-2022)

    • Figure Global Application 2 Consumption and Growth Rate (2017-2022)

    • Figure Global Application 3 Consumption and Growth Rate (2017-2022)

    • Figure Global Type 1 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Type 2 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Type 3 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Application 1 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Application 2 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Application 3 Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Non-alcoholic Fatty Liver Disease (NAFLD) Drug Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Non-alcoholic Fatty Liver Disease (NAFLD) Drug Export by Region (Top 5 Countries) (2017-2028)

    • Table Metabolic Solutions Development (Foundation Year, Company Profile and etc.)

    • Table Metabolic Solutions Development Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Metabolic Solutions Development Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • Table Galmed International (Foundation Year, Company Profile and etc.)

    • Table Galmed International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Galmed International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • Table Kyorin Pharmaceutical (Foundation Year, Company Profile and etc.)

    • Table Kyorin Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Kyorin Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • Table Raptor Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Raptor Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Raptor Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • Table TCM Biotech International (Foundation Year, Company Profile and etc.)

    • Table TCM Biotech International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table TCM Biotech International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • Table Daewoong Pharmaceutical (Foundation Year, Company Profile and etc.)

    • Table Daewoong Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Daewoong Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • Table Phenex Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Phenex Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Phenex Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • Table Novartis AG (Foundation Year, Company Profile and etc.)

    • Table Novartis AG Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis AG Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • Table Zafgen (Foundation Year, Company Profile and etc.)

    • Table Zafgen Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Zafgen Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • Table Verva Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Verva Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Verva Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • Table Tobira Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Tobira Therapeutics Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Tobira Therapeutics Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service

    • Table Conatus Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Conatus Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Conatus Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US